Conservative treatment of XXXX in @entity950 and childhood with @entity4020 .

@entity1 @entity4020 @entity2695 @entity5 @entity221 @entity2490 @entity1431 @entity1129 @entity230 @entity1443 @entity950 @entity288
@entity2695 is the most common @entity5 of @entity950 . Most @entity2695 proliferate for 8 to 18 months and then slowly regress over the next 5 to 8 years. So far, @entity230 have been the established means of treatment, but there have been some reports of the use of @entity4020 (IFN-A2a) in such @entity5 . To evaluate the efficacy of IFN-A2a in treating @entity2695 in @entity950 and childhood, we administered it to ten @entity1 aged 4 h to 6.5 years with life-threatening @entity2695 in various parts of the body. The dose used was 3 MU/m2 body surface area subcutaneously every second day. All @entity1 had previously received @entity288 for 2 to 5 weeks without obvious success. The results were satisfactory: five @entity1 had total or almost total regression; the rest have had partial regression while treatment is still in progress. @entity1129 with @entity221 , @entity2490 , etc. accompanied the injections in some @entity1 . The symptoms were controlled with @entity1443 as necessary. Mild, transient @entity1431 occurred in some @entity1 as well, but subsided after cessation of therapy for 1 week. IFN-A2a appears to be a promising and well-tolerated element in the treatment of life-threatening @entity2695 in @entity950 and childhood.
